China 
Africa 
Explore chapters and articles related to this topic
Herbal Treatment for Irritable Bowel Syndrome
Published in Megh R. Goyal, Preeti Birwal, Durgesh Nandini Chauhan, Herbs, Spices, and Medicinal Plants for Human Gastrointestinal Disorders, 2023
Hasya Nazh Ekin, Didem Deliorman Orhan
The effect of standardized dry P. ginseng leaf and stem extract (containing 26.66% of total ginsenosides) on abdominal pain in IBS patients was assessed by a double-blind, prospective, and randomized clinical experimental study. The patients (n = 24) were chosen based on Rome III criteria and were divided into two groups each with 12 patients. The P. ginseng was given to the first group at 300 mg/day dose daily. To the latter group, trimebutine (600 mg/day) was given. The condition of the patients was evaluated at baseline, after 1 week, 30 and 60 days. For the determination of the severity of the pain, the Likert scale was used: (1) the scale at −7 that indicated the enormous pain and (2) the scale at (+7) that indicated painless symptoms. After 8 weeks of the treatment, it is shown that the pain scores in all patients in both groups become positive and indicated significant differences when compared to the baseline (p < 0.05). Furthermore, no significant differences were shown between P. ginseng and trimebutine (positive control) groups. In the group that used P. ginseng, two patients (16.66%) experienced a headache as a side effect. In the study, the positive effect of P. ginseng on IBS patients was attributed to the body tonic and antinociceptive activity of the plant.
Trimebutine
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Trimebutine is a trimethoxybenzoic acid and spasmolytic agent that regulates intestinal and colonic motility and relieves abdominal pain with antimuscarinic and weak mu opioid agonist effects. This drug is indicated for symptomatic treatment of irritable bowel syndrome and treatment of postoperative paralytic ileus following abdominal surgery (1). It is also used rectally and topically for anal fissures and hemorrhoids (2). In pharmaceutical products, both trimebutine and trimebutine maleate (CAS number 34140-59-5, EC number 251-845-9, molecular formula C26H33NO9) may be employed (1).
Rational Medical Therapy of Functional GI Disorders
Published in Kevin W. Olden, Handbook of Functional Gastrointestinal Disorders, 2020
Richard M. Sperling, Kenneth R. McQuaid
Antispasmodic agents have been used in the treatment of IBS. They are believed to work by causing direct relaxation of the smooth muscle of the GI tract, thus decreasing colonic motor activity. Hence, the rationale supporting their use in IBS is similar to that for anticholinergic agents. The agents that have undergone the most clinical testing include mebeverine, trimebutine, ocylonium (none of which is available in the United States), and, more recently, calcium channel blockers. Mebeverine is a potent smooth-muscle relaxant that is similar in action to papaverine (an agent approved for the treatment of vascular and ureteral spasm) and devoid of anticholinergic action. Trimebutine is another spasmolytic agent with complex actions of the GI tract. It causes increased small-bowel motility through stimulation of peripheral opioid receptors but inhibition of colonic motility through a naloxone-sensitive pathway (162). Octylonium is an antispasmodic that is thought to work through inhibition of calcium mobilization. It has been shown to decrease postprandial colonic motility in patients with IBS (163).
The protective impact of adapted trimebutine maleate-loaded nanostructured lipid carriers for alleviating the severity of acute colitis
Published in Drug Delivery, 2022
Amira Motawea, Walaa Ebrahim Abd El Hady, Ghada Ahmed El-Emam
Trimebutine maleate was kindly obtained from the National Organization of Drug Control and Research (NODCAR) (Cairo, Egypt). Glyceryl monostearate pellets (m.p. 57–65 °C), Compritol 888 ATO (glyceryl behenate) pellets (m.p. 65–77 °C), Precirol ATO 5 pellets (m.p. 50.0–60.0 °C), Peceol TM (glyceryl monooleate), Miglyol® 812 N, Capryol 90, Labrafac PG (propylene glycol dicaprylocaprate), Gelucire 43/01 were obtained as a gift from Gattfosee Co. Saint-priest, Cedex, France. Poloxamer188 (pluronic F-68) M Wt. 7680–9510 Da was purchased from BASF Corp. (Ludwigshafen, Germany). Tween® 80 polysorbate, sodium chloride (NaCl), glacial acetic acid, castor oil, and stearic acid were kindly provided by Adwic, El Nasr, Pharmaceutical Chemicals Co. (Cairo, Egypt). Absolute ethyl alcohol was obtained from Fisher Scientific Co. (Schwerte, Germany). Oxidative stress markers assay kits were obtained from Biodiagnostic Co. (Giza, Egypt). Tumor necrosis factor-α antibodies were procured from Novus Biologicals (Centennial, CO). Other materials were of analytical grade.
Hydrogen sulfide: a target to modulate oxidative stress and neuroplasticity for the treatment of pathological anxiety
Published in Expert Review of Neurotherapeutics, 2020
Mary Chen, Caroline Pritchard, Diandra Fortune, Priyadurga Kodi, Marco Grados
In another H2S moiety attachment model, trimebutine received an H2S-releasing counterion (3-thiocarbamoylbenzoate, 3TCB), resulting in an H2S-releasing compound candidate. Trimebutine is a noncompetitive spasmolytic agent which uses peripheral mu- and kappa-opioid receptors and has been used in colonoscopy procedures, while the H2S-releasing salt has been tested in a mouse model of colorectal distension. Compared to trimebutine, the H2S-releasing salt compound (GIC-1001) significantly reduced nociceptive responses in affected mice [104].